- Details
- (Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...
|
- Details
- (Length of Discussion: 10 min) David Penson and Alicia Morgans share views on the evolution of the United States Preventive Services Task Force, USPSTF's recommendations for PSA screening. What do the recent changes mean to the clinician and the patient when making individual decisions regarding screening. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E. Howd Ch...
|
- Details
- (Length of Discussion: 12 min) Susan Halabi, the first biostatistician to become a fellow of ASCO, discusses recent data on overall survival in prostate cancer for black versus white men with Alicia Morgans and Charles Ryan. Susan discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had metastatic castration-resistant prostate canc...
|
- Details
- (Length of Discussion: 16 min) An emerging expert in the field of genetics and prostate cancer, Heather Cheng speaks with Charles Ryan in a thought-provoking dialogue of genetic evaluation and counseling for patients with prostate cancer. They review a variety of the genes that are involved in both DNA repair as well as the Lynch Syndrome, wrapping up with a discussion about PARP Inhibitors. Biogr...
|
- Details
- (Length of Discussion: 10 min) Edward (Ted) Schaeffer, MD, Ph.D. and Alicia Morgans, MD share a dynamic discussion on the risk strategy that may be employed for high-risk prostate cancer patients including oligometastatic disease. They share observations such as an increase in patient volume in their clinics of men with rising PSAs, high grade and locally advanced disease. In discussing the best w...
|
- Details
- (Length of Discussion: 7 min) Stacy Loeb, MD, and Alicia Morgans, MD discuss conservative management, active surveillance, and management trends over time for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System over the past decade. Biographies: Stacy Loeb, MD, is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prosta...
|
- Details
- (Length of Conversation: 10 min) Alex Kutikov, MD, FACS talks with Alicia Morgans, MD, MPH on the multidisciplinary management of genitourinary oncology and his experiences at Fox Chase Cancer Center. This discussion includes the importance of the collaborative care for the patient from the radiation oncologist, medical oncologist, and urologist and the nuances of this co-management with the numbe...
|
- Details
- (Length of Discussion: 12 min) Daniel George, MD talks with Charles Ryan, MD and discusses a number of recent studies Daniel and his colleagues at Duke University School of Medicine have been focused on related to race and abiraterone outcomes in prostate cancer patients and how this new information impacts clinical practice. Studies and Presentations Discussed in Discussion: Overall Survival Betw...
|
- Details
- (Length of Presentation: 20 min) Jehonathan Pinthus presents the role of androgen deprivation therapy (ADT) in promoting cardiovascular disease (CVD) and focuses on two prospective studies, one of which is embedded in the other. The Role of Androgen Deprivation Therapy in Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) is a prospective cohort study of men within one yea...
|
- Details
- (Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...
|
